We wanted to compare clinical neurological and antisaccadic behavior before and after addition of a dopamine agonist to the usual antiparkinsonian drugs in advanced Parkinson’s disease. Parkinson’s patients in stage 3 and 4 of Hoehn and Yahr not yet taking a dopamine agonist were selected. In 20 patients, the treating neurologist decided to add pergolide. The dose of pergolide was adjusted by the treating neurologist according to clinical response. Antisaccades were studied by infrared oculography before and after addition of pergolide. Antisaccades are voluntary saccades in the opposite direction of an unanticipated visual target. The patients made more errors, i.e. they glanced to the target or they made no eye movement at all. In contradistinction to the global neurological improvement and the better motor scores, antisaccadic disturbances did not improve significantly with pergolide, except in younger patients. These findings suggest that antisaccadic alterations in patients with advanced Parkinson’s disease could be multifaceted. Not only depletion of dopamine, but also non-dopaminergic dysfunctions could contribute. Cortical frontal lesions must also be taken into account.

Keywords:
Antisaccade, Parkinson’s disease, Dopamine agonist, Pergolide, Frontal lesion
This content is only available via PDF.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.